Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

398 ARTÍCULOS , VIENDO DEL 106 AL 120

Novel Therapeutic Potentials of Taxifolin for Amyloid-β-associated Neurodegenerative Diseases and Other Diseases: Recent Advances and Future Perspectives

Tanaka M, Saito S, Inoue T, Satoh-Asahara N, Ihara M.

Int J Mol Sci. 2019 Apr 30;20(9):2139. doi: 10.3390/ijms20092139.

Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer's disease

Connelly PJ, Adams F, Tayar ZI, Khan F.

BMC Neurol. 2019 May 3;19(1):88. doi: 10.1186/s12883-019-1316-4.

Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus

Ohyagi Y, Miyoshi K, Nakamura N.

Adv Exp Med Biol. 2019;1128:227-248. doi: 10.1007/978-981-13-3540-2_11.

Editorial: Failure After Failure. What Next in AD Drug Development?

Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):150. doi: 10.14283/jpad.2019.23.

Silymarin's Inhibition and Treatment Effects for Alzheimer's Disease

Guo H, Cao H, Cui X, Zheng W, Wang S, Yu J, Chen Z.

Molecules. 2019 May 6;24(9):1748. doi: 10.3390/molecules24091748.

Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease

Ma SL, Tang NLS, Wat KHY, Tang JHY, Lau KH, Law CB, Chiu J, Tam CCW, Poon TK, Lin KL, Kng CPL, Kong HL, Chan TY, Chan WC, Lam LCW.

Am J Alzheimers Dis Other Demen. 2019 Aug;34(5):302-307. doi: 10.1177/1533317519848237. Epub 2019 May 7.

Natural Compounds for Alzheimer's Disease Therapy: A Systematic Review of Preclinical and Clinical Studies

Andrade S, Ramalho MJ, Loureiro JA, Pereira MDC.

Int J Mol Sci. 2019 May 10;20(9):2313. doi: 10.3390/ijms20092313.

Development and validation of Alzheimer's Disease Animal Model for the Purpose of Regenerative Medicine

Goodarzi P, Payab M, Alavi-Moghadam S, Larijani B, Rahim F, Bana N, Sarvari M, Adibi H, Foroughi Heravani N, Hadavandkhani M, Arjmand B.

Cell Tissue Bank. 2019 Jun;20(2):141-151. doi: 10.1007/s10561-019-09773-8. Epub 2019 May 13.

NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms

Beaver SK, Mesa-Torres N, Pey AL, Timson DJ.

Biochim Biophys Acta Proteins Proteom. 2019 Jul-Aug;1867(7-8):663-676. doi: 10.1016/j.bbapap.2019.05.002. Epub 2019 May 12.

Tau immunotherapies for Alzheimer's disease

Hoskin JL, Sabbagh MN, Al-Hasan Y, Decourt B.

Expert Opin Investig Drugs. 2019 Jun;28(6):545-554. doi: 10.1080/13543784.2019.1619694. Epub 2019 May 22.

Tackling Alzheimer's disease: Hypothetical synergism between anti-inflammatory and anti-diabetic agents

Łuc M, Woźniak M, Helemejko M, Rymaszewska J.

Life Sci. 2019 Aug 15;231:116483. doi: 10.1016/j.lfs.2019.05.039. Epub 2019 May 15.

Multi-target design strategies for the improved treatment of Alzheimer's disease

Zhang P, Xu S, Zhu Z, Xu J.

Eur J Med Chem. 2019 Aug 15;176:228-247. doi: 10.1016/j.ejmech.2019.05.020. Epub 2019 May 11.

Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors

Kuo YC, Rajesh R.

Expert Rev Neurother. 2019 Jul;19(7):623-652. doi: 10.1080/14737175.2019.1621750. Epub 2019 May 29.

A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned

Modrego P, Lobo A.

Neurodegener Dis Manag. 2019 Jun;9(3):119-121. doi: 10.2217/nmt-2019-0006. Epub 2019 May 22.

Neuroprotective effects of berberine in animal models of Alzheimer's disease: a systematic review of pre-clinical studies

Yuan NN, Cai CZ, Wu MY, Su HX, Li M, Lu JH.

BMC Complement Altern Med. 2019 May 23;19(1):109. doi: 10.1186/s12906-019-2510-z.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias